Клинические исследования эффективности химиотерапии в сочетании с андрогенной депривацией у пациентов с олигометастатическим гормоночувствительным раком предстательной железы

СтатьяМЕД СОВЕТ. 2019; № 19: 170–175. DOI:10.21518/2079-701X-2019-19-170-175

Попов С.В.^[1]

^[1]Российский университет дружбы народов (Москва)

рак предстательной железы

гормоночувствительность

олигометастазы

андроген-депривационная терапия

химиотерапия

доцетаксел

эффективность

Андрогены

Больные

Выживаемость

Доцетаксел

Железо

Клиническое исследование

Лекарственная терапия

Новообразований метастазы

Предстательная железа

Предстательной железы новообразования

Риск

Каприн А.Д., Старинский В.В., Петрова Г.В. (ред.). Состояние онкологической помощи населению России в 2018 году. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2019. 236 с. Режим доступа: http://www.oncology.ru/service/statistics/condition/2018.pdf.http://www.oncology.ru/service/statistics/condition/2018.pdf

Алексеев Б.Я., Андрианов А.Н., Каприн А.Д. Современные подходы к выбору терапии 1-й линии больных метастатическим гормоночувствительным раком предстательной железы. Онкоурология. 2017;13(4):85-90. doi: 10.17650/1726-9776-2017-13-4-85-90..
DOI: 10.17650/1726-9776-2017-13-4-85-90

Hellman S., Weichselbaum R.R. Oligometastases WRR. Oligometastases. J Clin Oncol. 1995;13:8–10. doi: 10.1200/JCO.1995.13.1.8..
DOI: 10.1200/JCO.1995.13.1.8

Ost P., Jereczek- Fossa B.A., As N.V., Zilli T., Muacevic A., Olivier K. et al. Progression-free survival following stereotactic body radiotherapy for oligometastatic prostate cancer treatment-naive recurrence: a multi-institutional analysis. Eur Urol. 2016;69:9–12. doi: 10.1016/j.eururo.2015.07.004..
DOI: 10.1016/j.eururo.2015.07.004

Pasqualetti F., Panichi M., Sainato A., Baldaccini D., Cocuzza P., Gonnelli A. et al. Image-guided stereotactic body radiotherapy in metastatic prostate cancer. Anticancer Res. 2018;38:3119–3122. doi: 10.21873/anticanres.12572..
DOI: 10.21873/anticanres.12572

Gravis G., Fizazi K., Joly F., Oudard S., Priou F., Esterni B. et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(2):149–158. doi: 10.1016/S1470-2045(12)70560-0..
DOI: 10.1016/S1470-2045(12)70560-0

Sweeney C.J., Chen Y.H., Carducci M., Liu G., Jarrard D.F., Eisenberger M. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373:737–746. doi: 10.1056/NEJMoa1503747..
DOI: 10.1056/NEJMoa1503747

James N.D., Sydes M.R., Clarke N.W., Mason M.D., Dearnaley D.P., Spears M.R. et al.; STAMPEDE investigators. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387:1163–1177. doi: 10.1016/S0140-6736 (15)01037-5..
DOI: 10.1016/S0140-6736 (15)01037-5

James N.D., Sydes M.R., Clarke N.W., Mason M.D., Dearnaley D.P., Spears M.R. et al.; STAMPEDE investigators. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387:1163–1177. doi: 10.1016/S0140-6736 (15)01037-5..
DOI: 10.1016/S0140-6736(15)01037-5

Fizazi K., Jenkins C., Tannock I.F. Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra. Ann Oncol. 2015;26(8):1660–1667. doi: 10.1093/annonc/mdv245..
DOI: 10.1093/annonc/mdv245

Shenoy N., Kohli M. Role of systemic chemotherapy in metastatic hormone-sensitive prostate cancer. Indian J Urol. 2016;32:257-261. doi: 10.4103/0970-1591.191234..
DOI: 10.4103/0970-1591.191234

Puente J., Grande E., Medina A., Maroto P., Lainez N., Arranz J.A. Docetaxel in prostate cancer: a familiar face as the new standard in a hormone-sensitive setting. Ther Adv Med Oncol. 2017;9(5):307–318. doi: 10.1177/1758834017692779..
DOI: 10.1177/1758834017692779

Vale C.L., Burdett S., Rydzewska L.H.M., Albiges L., Clarke N.W., Fisher D., et al., for the STOpCaP Steering Group. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and metaanalyses of aggregate data. Lancet Oncol. 2016;17(2):243–256. doi: 10.1016/S1470-2045(15)00489-1..
DOI: 10.1016/S1470-2045(15)00489-1

Kapoor A. What’s New in Prostate Cancer Research? Highlights of GU-ASCO 2015. Can Urol Assoc J. 2015;9(5-6Suppl3):S148–S153. doi: 10.5489/cuaj.2994..
DOI: 10.5489/cuaj.2994

Botrel T.E.A., Clark O., Pompeo A.C.L., Bretas F.F.H., Sadi M.V., Ferreira U., Borges dos Reis R. Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis. PLoS One. 2016;11(6):e0157660. doi: 10.1371/journal.pone.0157660..
DOI: 10.1371/journal.pone.0157660

Damodaran S., Kyriakopoulos C.E., Jarrard D.F. Newly diagnosed metastatic prostate cancer – has the paradigm changed? Urol Clin North Am. 2017;44(4):611–621. doi: 10.1016/j.ucl.2017.07.008..
DOI: 10.1016/j.ucl.2017.07.008

Kapoor A., Hotte S.J. Androgen receptor axis-targeted agents. Can Urol Assoc J. 2016;10(7-8Suppl3):S146–S148. doi: 10.5489/cuaj.4057..
DOI: 10.5489/cuaj.4057

Merseburger A.S., Alcaraz A., von Klot C.A. Androgen deprivation therapy as backbone therapy in the management of prostate cancer. Onco Targets Ther. 2016;9:7263–7274. doi: 10.2147/OTT.S117176..
DOI: 10.2147/OTT.S117176

Shiota M., Yokomizo A., Eto M. Taxane Chemotherapy for Hormone-Naïve Prostate Cancer with Its Expanding Role as Breakthrough Strategy. Front Oncol. 2015;5:304. doi: 10.3389/fonc.2015.00304..
DOI: 10.3389/fonc.2015.00304

Chen J., Zhang X., Sun G., Zhao J., Liu J., Zhao P., Dai J., Shen P., Zeng H. The effect of additional chemotherapy on high-risk prostate cancer: a systematic review and meta-analysis. Onco Targets Ther. 2018;11:9061–9070. doi: 10.2147/OTT.S187239..
DOI: 10.2147/OTT.S187239

Komura K., Sweeney C.J., Inamoto T., Ibuki N., Azuma H., Kantoff P.W. Current treatment strategies for advanced prostate cancer. Int J Urol. 2018;25(3):220–231. doi: 10.1111/iju.13512..
DOI: 10.1111/iju.13512

Sathianathen N.J., Philippou Y.A., Kuntz G.M., Konety B.R., Gupta S., Lamb A.D., Dahm P. Taxane‐based chemohormonal therapy for metastatic hormone‐sensitive prostate cancer. Cochrane Database Syst Rev. 2018;(10):CD012816. doi: 10.1002/14651858.CD012816.pub2..
DOI: 10.1002/14651858.CD012816.pub2

Nader R., Amm J.E., Aragon-Ching J.B. Role of chemotherapy in prostate cancer. Asian J Androl. 2018;20(3):221-229. doi: 10.4103/aja.aja_40_17..
DOI: 10.4103/aja.aja_40_17

Gravis G. Systemic treatment for metastatic prostate cancer. Asian J Urol. 2019;6(2):162–168. doi: 10.1016/j.ajur.2019.02.002..
DOI: 10.1016/j.ajur.2019.02.002

Hurwitz M.D. Chemotherapy and radiation for prostate cancer. Transl Androl Urol. 2018;7(3): 390–398. doi: 10.21037/tau.2018.03.07..
DOI: 10.21037/tau.2018.03.07

Miura Y., Horie S. The role of hormone therapy and chemotherapy in oligometastatic prostate cancer. ESMO Open. 2019;4(Suppl 1):e000471. doi: 10.1136/esmoopen-2018-000471..
DOI: 10.1136/esmoopen-2018-000471

Cornford P., Bellmunt J., Bolla M., Briers E., De Santis M., Gross T. et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71:630–642. doi: 10.1016/j.eururo.2016.08.002..
DOI: 10.1016/j.eururo.2016.08.002

Грицкевич А.А., Мишугин С.В., Русаков И.Г. Возможности комбинации доцетаксела с андрогенной депривацией при инициальной терапии гормоночувствительного рака предстательной железы. Медицинский совет. 2017;(6):94-97. doi: 10.21518/2079-701X-2017-6-94-97..
DOI: 10.21518/2079-701X-2017-6-94-97

Gravis G., Boher J.M., Joly F., Soulié M., Albiges L., Priou F. et al.; GETUG. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non- castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur Urol. 2016;70:256–62. doi: 10.1016/j.eururo.2015.11.005..
DOI: 10.1016/j.eururo.2015.11.005

Kyriakopoulos C.E., Chen Y.H., Carducci M.A., Liu G., Jarrard D.F., Hahn N.M. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol. 2018;36:1080–1087. doi: 10.1200/JCO.2017.75.3657..
DOI: 10.1200/JCO.2017.75.3657

Tucci M., Bertaglia V., Vignani F., Buttigliero C., Fiori C., Porpiglia F., Scagliotti G.V., Di Maio M. Addition of docetaxel to androgen deprivation therapy for patients with hormone-sensitive metastatic prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016;69:563–573. doi: 10.1016/j.eururo.2015.09.013..
DOI: 10.1016/j.eururo.2015.09.013

Язык текста: Русский

ISSN: 2079-701X